Quince Therapeutics Posts $12.31 Q2 Loss Per Share
QNCX has more than doubled off its 52-week low of $15.1.
Summary
Quince Therapeutics reported a Q2 loss of $12.31 per share, a significant figure relative to its $32.5 stock price and $33M market cap. The company's Q2 net loss was $75.5M, widening on acquisition charges. The loss follows a Q1 that showed net income only due to non-cash restructuring gains, so this quarter reveals the underlying cash burn. The company has been using aggressive reverse splits and ATM raises to stay listed, and this loss underscores the ongoing going-concern risk. With a pending special meeting in September to approve preferred stock conversion and warrants, dilution pressure remains high. The company has runway to fund operations through end 2028.
Updates
· SEC 10-Q — The 10-Q discloses $116.0M cash as of June 30, 2026, and states substantial doubt about its ability to continue as a going concern within one year.
At the time of this announcement, QNCX was trading at $32.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33M. The 52-week trading range was $15.10 to $909.98. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.